Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019)

Select coverage from The Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) is included below:

Can Gene Editing Tool CRISPR Dispense With HIV?
A study using monkeys provides an intriguing glimpse of the possibilities of using CRISPR gene editing technology to knock out HIV reserves in humans.
How Does Hormonal Contraception Affect a Woman's HIV Risk?
Melanie Nicol, PharmD, PhD, explores how DMPA hormonal contraception affects women's HIV risk.
Implants of Tenofovir Alafenamide Could Provide Protection for 6 Months, Study Says
Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.
What Do Long-Acting Injectables Offer Patients With HIV?
Brian Woodfall, MD, discusses how long-acting injectables offer a new treatment option for patients with HIV in terms of long-term therapy.
DISCOVER Study Showing TAF/FTC Noninferiority Is 'Encouraging'
Paul Sax, MD, names the DISCOVER study as one of the highlights of CROI 2019.
Treating Pregnant Women With HIV
Saye Khoo, MD, advocates for a more appropriate, stratified, risk-based approach to prescribing dolutegravir in pregnant women. 
Why Is It So Important to Continue to Develop New Antiretroviral Therapies?
Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.
Advancements in HIV Treatment and Prevention
Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.
FEATURED
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.